<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04316039</url>
  </required_header>
  <id_info>
    <org_study_id>ChiCTR1800015199</org_study_id>
    <nct_id>NCT04316039</nct_id>
  </id_info>
  <brief_title>Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery</brief_title>
  <official_title>Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been reported that radiation therapy followed by PCV chemotherapy (procarbazine,
      lomustine and vincristine) could improve progression-free survival (PFS) and overall survival
      (OS) in patients with high-risk WHO grade 2 gliomas after surgery. However, procarbazine is
      not available in China. In clinical practice, Chinese doctors often use radiotherapy combined
      with temozolomide to treat these patients, though large-scale prospective studies are
      lacking. This trial aims to confirm whether RT combined with temozolomide can improve PFS and
      OS in patients with high-risk low-grade gliomas.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 120 months</time_frame>
    <description>Our primary outcome is progression-free survival which is calculated from the date of randomization to the date of first reported disease progression or the date of death.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Low-grade Glioma</condition>
  <arm_group>
    <arm_group_label>RT+TMZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Concurrent chemotherapy is to receive oral temozolomide, 75 mg/m2 per day, during radiation therapy. Adjuvant chemotherapy will be treated with six cycles of temozolomide, 150 to 200 mg/m2 per day for five consecutive days, repeated every 4 weeks. There is a 28-day break during radiotherapy and adjuvant temozolomide.</description>
    <arm_group_label>RT+TMZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity modulated radiation therapy</intervention_name>
    <description>The radiation dose is 50-54 Gy given in 25-30 fractions (1.8-2.0 Gy once daily, 5 days per week).</description>
    <arm_group_label>RT</arm_group_label>
    <arm_group_label>RT+TMZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly diagnosed supratentorial WHO grade II gliomas;

          2. Aged 18 to 39 years without total resection, or aged 40 to 70 years with any extent of
             resection or biopsy;

          3. Karnofsky performance score (KPS) â‰¥ 60;

          4. No more than moderate neurologic symptoms and signs;

          5. The interval between surgery and randomization is less than 12 weeks;

          6. Have signed the consent form. -

        Exclusion Criteria:

          1. WHO grade I gliomas or high-grade gliomas according to WHO's grading system;

          2. Have received prior radiation therapy to the head and neck region;

          3. Have received prior chemotherapy;

          4. Synchronous multiple primary malignant tumor excluding carcinoma of the cervix in situ
             or nonmelanomatous skin cancer;

          5. Prior malignancy's disease-free survival less than 5 years;

          6. Have active infection;

          7. Patients are pregnant or breast-feeding. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xingchen Peng, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xingchen Peng, Ph.D</last_name>
    <phone>+86 18980606753</phone>
    <email>pxx2014@scu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xingchen Peng</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingchen Peng, Ph.D</last_name>
      <phone>+8618980606753</phone>
      <email>pxx2014@scu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Xingchen Peng</investigator_full_name>
    <investigator_title>PhD, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>low-grade glioma</keyword>
  <keyword>High-risk</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Temozolomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

